At close: December 20 at 4:00:03 PM EST
Pre-Market: 6:39:38 AM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | -0.15 | -0.15 | -0.76 | -0.68 |
| Low Estimate | -0.17 | -0.15 | -0.86 | -0.73 |
| High Estimate | -0.13 | -0.15 | -0.6 | -0.59 |
| Year Ago EPS | -0.12 | -0.17 | -0.25 | -0.76 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 4 | 6 | 6 |
| Avg. Estimate | 250k | -- | 554.33k | 250k |
| Low Estimate | -- | -- | 300k | -- |
| High Estimate | 1.5M | -- | 1.8M | 1.5M |
| Year Ago Sales | 18k | -- | 214k | 554.33k |
| Sales Growth (year/est) | 1,288.89% | 0.00% | 159.03% | -54.90% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.18 | -0.16 | -0.16 |
| EPS Actual | -0.12 | -0.17 | -0.36 | -0.16 |
| Difference | 0.04 | 0.01 | -0.2 | 0 |
| Surprise % | 26.15% | 5.56% | -129.78% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.15 | -0.76 | -0.68 |
| 7 Days Ago | -0.18 | -0.18 | -0.78 | -0.73 |
| 30 Days Ago | -0.18 | -0.18 | -0.78 | -0.73 |
| 60 Days Ago | -0.18 | -0.18 | -0.78 | -0.73 |
| 90 Days Ago | -0.18 | -0.18 | -0.78 | -0.73 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ATAI | -25.00% | 11.76% | -202.67% | 10.57% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/18/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/18/2024 |
Related Tickers
CYBN Cybin Inc.
9.61
+3.11%
MNMD Mind Medicine (MindMed) Inc.
7.16
+2.07%
GHRS GH Research PLC
6.85
-7.31%
CYBN.NE Cybin Inc.
13.70
+2.85%
NUVB Nuvation Bio Inc.
2.6800
-0.37%
IGXT IntelGenx Technologies Corp.
0.1700
0.00%
ATRA Atara Biotherapeutics, Inc.
11.40
+14.80%
ATYR aTyr Pharma, Inc.
3.3500
+6.35%
MDMA.CN Pharmala Biotech Holdings Inc.
0.2350
-2.08%
NRXP NRx Pharmaceuticals, Inc.
1.5000
-1.32%